• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virology . Adjuvants enhance protective antibodies against seasonal influenza viruses following a single vaccination of Fluzone

tetano

Editor, Senior Moderator
Virology


. 2026 Jan 6:616:110787.
doi: 10.1016/j.virol.2026.110787. Online ahead of print. Adjuvants enhance protective antibodies against seasonal influenza viruses following a single vaccination of Fluzone

Matthew H Thomas[SUP] 1 [/SUP], Michael A Carlock[SUP] 1 [/SUP], Ted M Ross[SUP] 2 [/SUP]



Affiliations
Free article Abstract

Fluzone is a commercial, split-inactivated influenza virus vaccine produced from embryonated chicken eggs and administered via intramuscular injection. One strategy to increase the potency of this vaccine is to formulate with an effective adjuvant. To address this goal, mice were vaccinated with Fluzone mixed with either squalane oil-in-water adjuvant (Addavax) or a combination of a synthetic toll-like receptor (TLR) 4 and TLR7/8 agonist (TRAC478). Mice vaccinated with vaccine plus adjuvant had higher anti-HA binding antibodies and hemagglutination-inhibition (HAI) titers than mice administered unadjuvanted vaccine following a single vaccination. In general, mice vaccinated with Fluzone plus TRAC478 had higher HAI and neutralizing titers after the first vaccination compared to mice vaccinated with Fluzone plus Addavax. All vaccinated mice challenged with an H1N1 influenza virus (A/Brisbane/02/2018) lost little weight and survived challenge. Mice vaccinated with Fluzone plus either adjuvant had no detectable lung viral titers at day 3 post-challenge. Mice vaccinated with unadjuvanted Fluzone or mock vaccinated mice had 3-5 log higher viral titers. Vaccinated mice challenged with an H3N2 influenza virus (A/Switzerland/9715293/2013) lost, on average, 10-15 % of their original body weight by day 3 post-challenge but slowly recovered with viral lung titers that were 2-2.5 logs lower than mice administered unadjuvanted Fluzone. Lungs collected from mice vaccinated with Fluzone plus TRAC478 had low levels of lung infiltrating cells following a single vaccination. Overall, the use of adjuvant, particularly TRAC478, enhanced the elicitation of protective antibodies elicited by Fluzone following a single vaccination.

Keywords: Adjuvant; Influenza; Split-inactivated influenza virus vaccine.

 
Back
Top Bottom